Keywords: Britsol-Myers Squibb, Brivanib, Ph III, Hepatocellular carcinoma, Liver cancer

Bristol-Myer’s brivanib disappoints in Ph III study

Article | 28 December 2011

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) has revealed disappointing results of a Phase III trial with the firm’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in